<DOC>
	<DOCNO>NCT00407849</DOCNO>
	<brief_summary>Phase I/II study intravitreal triamcinolone acetonide microspheres ( RETAAC ) treatment diffuse diabetic macular edema unresponsive laser photocoagulation . Study hypothesis single intravitreal injection RETAAC safe efficient compare conventional treatment . Fifty patient participate study randomize treatment observation group . Efficacy evaluate best correct visual acuity macular thickness measure optic coherence tomography ( OCT ) 12 month treatment .</brief_summary>
	<brief_title>Intravitreal Triamcinolone Acetonide Treatment Refractory Diffuse Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Diabetes mellitus ( type 1 2 ) Diabetic macular edema study eye associate diabetic retinopathy Diffuse macular edema define macular thickening determine biomicroscopy fluorescein angiography . Best correct visual acuity 34 ( 20/200 ) 68 letter ( 20/50 ) . Macular thickness great 300 mcm OCT. Uncontrolled systemic disease Start medical therapy diabetes change treatment oral insulin four month initial visit . HbA1c level great 10 % Presence retinal venous occlusion , cystoid macular edema , condition would contribute macular edema . Presence epiretinal membrane Presence vitreomacular traction study eye . Aphakic anterior chamber intraocular lens study eye . Neovascularization disc elsewhere study eye . History presence choroidal neovascularization study eye . Presence rubeosis iris study eye . Eye opacity interfere clinical documentation photography . Intraocular surgery 90 day initial visit . Previous vitrectomy study eye . Previous history intravitreal periocular corticoid intravitreal drug study eye . Scheduled surgery study eye . Patients known allergy fluorescein , iodopovidone component study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>